Genetic Factors Influencing Warfarin Dose in Black-African Patients: A Systematic Review and Meta-Analysis.

Clin Pharmacol Ther 2019 Dec 23. Epub 2019 Dec 23.

Department of Molecular and Clinical Pharmacology, The Wolfson Centre for Personalized Medicine, MRC Centre for Drug Safety Science, University of Liverpool, Liverpool, UK.

Warfarin is the most commonly used oral anticoagulant in sub-Saharan Africa. Dosing is challenging due to a narrow therapeutic index and high interindividual variability in dose requirements. To evaluate the genetic factors affecting warfarin dosing in black-Africans, we performed a meta-analysis of 48 studies (2,336 patients). Significant predictors for CYP2C9 and stable dose included rs1799853 (CYP2C9*2), rs1057910 (CYP2C9*3), rs28371686 (CYP2C9*5), rs9332131 (CYP2C9*6), and rs28371685 (CYP2C9*11) reducing dose by 6.8, 12.5, 13.4, 8.1, and 5.3 mg/week, respectively. VKORC1 variants rs9923231 (-1639G>A), rs9934438 (1173C>T), rs2359612 (2255C>T), rs8050894 (1542G>C), and rs2884737 (497T>G) decreased dose by 18.1, 21.6, 17.3, 11.7, and 19.6 mg/week, respectively, whereas rs7294 (3730G>A) increased dose by 6.9 mg/week. Finally, rs12777823 (CYP2C gene cluster) was associated with a dose reduction of 12.7 mg/week. Few studies were conducted in Africa, and patient numbers were small, highlighting the need for further work in black-Africans to evaluate genetic factors determining warfarin response.

Download full-text PDF

Source
http://dx.doi.org/10.1002/cpt.1755DOI Listing
December 2019

Publication Analysis

Top Keywords

genetic factors
12
evaluate genetic
8
dose
7
dose included
4
127 mg/week studies
4
stable dose
4
497t>g decreased
4
cyp2c9 stable
4
reduction 127 mg/week
4
variants rs9923231
4
cyp2c9*2 rs1057910
4
dose reduction
4
rs1799853 cyp2c9*2
4
predictors cyp2c9
4
included rs1799853
4
patients predictors
4
rs2359612 2255c>t
4
performed meta-analysis
4
black-africans performed
4
africa patient
4

Similar Publications